GlycoMimetics in manufacturing pact with Thermo Fisher for uproleselan

On January 2, GlycoMimetics (GLYC) entered into a project agreement with Patheon Manufacturing Services part of Thermo Fisher Scientific (TMO), pursuant to which Patheon will manufacture and supply the Company with its drug candidate, uproleselan, for commercial sale should the Company receive marketing approval from the U.S. Food and Drug Administration. The Project Agreement is subject to the additional terms of a Master Services Agreement previously entered into by the Company and Patheon that governs the general terms under which Patheon will provide non-exclusive manufacturing and commercial services to the Company from time to time…Pursuant to the Project Agreement, Patheon will manufacture commercial supplies of injectable uproleselan from active pharmaceutical ingredient supplied by the Company. Patheon will be responsible for supplying the other required raw materials and packaging components and will also provide supportive manufacturing services such as quality control testing for raw materials, packaging components and finished product. Under the Project Agreement, the Company has provided Patheon with its forecast of required annual volumes through 2027. The Project Agreement has an initial term through December 31, 2026 and will automatically renew for additional three-year periods unless earlier terminated. After the initial term, either party may terminate the Project Agreement by giving 18 months’ written notice for any business reason. Either party may terminate the Project Agreement within a given time period upon any material breach that is left uncured by the other party. Upon completion, expiration and/or termination of the Project Agreement, the Company will pay Patheon for all service rendered, all costs and expenses incurred and any termination fees. This information was provided in a company 8K filing.